Class information for:
Level 1: BIOCHEMOTHERAPY//METASTATIC MELANOMA//DACARBAZINE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
5301 1576 36.9 71%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
206 20344 MELANOMA//MALIGNANT MELANOMA//DERMOSCOPY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BIOCHEMOTHERAPY Author keyword 33 54% 3% 43
2 METASTATIC MELANOMA Author keyword 32 24% 8% 119
3 DACARBAZINE Author keyword 22 27% 4% 67
4 SONYA VALLEY GHIDOSSI VACCINE Address 10 52% 1% 13
5 ADJUVANT INTERFERON Author keyword 6 80% 0% 4
6 ALLOVECTIN 7 Author keyword 6 80% 0% 4
7 ADVANCED MELANOMA Author keyword 5 30% 1% 13
8 FOTEMUSTINE Author keyword 5 19% 1% 22
9 MELANOMA VACCINES Author keyword 4 67% 0% 4
10 ROY E COATS S Address 4 20% 1% 19

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 BIOCHEMOTHERAPY 33 54% 3% 43 Search BIOCHEMOTHERAPY Search BIOCHEMOTHERAPY
2 METASTATIC MELANOMA 32 24% 8% 119 Search METASTATIC+MELANOMA Search METASTATIC+MELANOMA
3 DACARBAZINE 22 27% 4% 67 Search DACARBAZINE Search DACARBAZINE
4 ADJUVANT INTERFERON 6 80% 0% 4 Search ADJUVANT+INTERFERON Search ADJUVANT+INTERFERON
5 ALLOVECTIN 7 6 80% 0% 4 Search ALLOVECTIN+7 Search ALLOVECTIN+7
6 ADVANCED MELANOMA 5 30% 1% 13 Search ADVANCED+MELANOMA Search ADVANCED+MELANOMA
7 FOTEMUSTINE 5 19% 1% 22 Search FOTEMUSTINE Search FOTEMUSTINE
8 MELANOMA VACCINES 4 67% 0% 4 Search MELANOMA+VACCINES Search MELANOMA+VACCINES
9 MALIGNANT METASTATIC MELANOMA 4 75% 0% 3 Search MALIGNANT+METASTATIC+MELANOMA Search MALIGNANT+METASTATIC+MELANOMA
10 DTIC 4 31% 1% 10 Search DTIC Search DTIC

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SEQUENTIAL CHEMOIMMUNOTHERAPY 91 81% 3% 55
2 DACARBAZINE 84 33% 13% 212
3 HIGH RISK MELANOMA 75 43% 8% 133
4 HIGH DOSE INTERFERON ALPHA 2B 48 59% 3% 54
5 RESECTED CUTANEOUS MELANOMA 39 61% 3% 42
6 DISSEMINATED MALIGNANT MELANOMA 38 45% 4% 63
7 METASTATIC MALIGNANT MELANOMA 37 25% 8% 127
8 CONCURRENT BIOCHEMOTHERAPY 32 65% 2% 31
9 ACTIVE SPECIFIC IMMUNOTHERAPY 27 19% 8% 124
10 DOSE INTERFERON ALPHA 2B 26 39% 3% 53

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis 2010 167 55 60%
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials 2003 175 20 85%
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? 2004 183 38 92%
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials 2003 166 56 71%
Chemotherapy for metastatic melanoma - Time for a change? 2007 105 55 80%
Treatment for metastatic malignant melanoma: Old drugs and new strategies 2010 45 92 72%
Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review 2013 9 46 76%
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma 2013 26 74 32%
The use of interferon in melanoma patients: A systematic review 2015 1 72 75%
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma 2006 74 39 90%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SONYA VALLEY GHIDOSSI VACCINE 10 52% 0.8% 13
2 ROY E COATS S 4 20% 1.2% 19
3 NO CALIF MELANOMA 4 75% 0.2% 3
4 PLAST SURG MICROSURG 4 38% 0.5% 8
5 UNIT MED ONCOL INNOVAT THER Y 3 35% 0.4% 6
6 CANC CLIN TRIALS GRP 2 67% 0.1% 2
7 MELANOMA PROGRAM 2 15% 0.8% 13
8 MELANOMA 2 11% 1.1% 18
9 UNIT 430 2 25% 0.4% 6
10 MELANOMA SARCOMA 2 20% 0.4% 7

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000132079 PATRICIA RITCHIE CANC CARE//EORTC QLQ C36//FEAR OF CANCER PROGRESSION
2 0.0000131480 THIN MELANOMA//SENTINEL LYMPH NODE//SYDNEY MELANOMA UNIT
3 0.0000107355 MIA//CIRCULATING MELANOMA CELLS//MELANOMA INHIBITORY ACTIVITY
4 0.0000087182 INTERLEUKIN 2//LYMPHOKINE ACTIVATED KILLER CELLS//RECOMBINANT INTERLEUKIN 2
5 0.0000085693 TRANSPLACENTAL METASTASIS//HTB63 HUMAN MELANOMA CELLS//PLACENTAL METASTASIS
6 0.0000085600 POLYVALENT ANTIGEN//AUTOLOGOUS ANTIBODY//B700
7 0.0000083218 CTLA 4//IPILIMUMAB//CYTOTOXIC T LYMPHOCYTE ANTIGEN 4
8 0.0000081011 VEMURAFENIB//B RAF//BRAF INHIBITOR
9 0.0000079015 ADV CELL MOL THER Y//SHUNDE PEOPLES HOSP//TUMOR VACCINE
10 0.0000076651 ANORECTAL MELANOMA//ANORECTAL MALIGNANT MELANOMA//PRIMARY MALIGNANT MELANOMA OF THE ESOPHAGUS